机构：[1]Hongqiao International Institute of Medicine, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.[2]Department of Pathology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
The liver and kidney are important metabolic organs in the body and common sites of tumor occurrence. Glycine-N-acyltransferase (GLYAT) is primarily expressed in the liver and kidney and downregulated in several tumors. But its specific functions and molecular mechanisms in liver cancer and clear cell renal cell carcinoma (ccRCC) have not yet been fully elucidated. The aim of this study was to explore the role and clinical significance of GLYAT in liver cancer and ccRCC.This study used proteomics technology to identify differentially expressed proteins in liver cancer. Western blot and immunohistochemistry (IHC) were used to analyze the protein expression pattern of GLYAT. assays were performed in liver cancer and ccRCC cells. Xenograft models in nude mice were used to confirm the roles of GLYAT in liver cancer. Moreover, the downstream regulatory proteins of GLYAT were identified by proteomics.GLYAT was lowly expressed in liver cancer and ccRCC. Immunofluorescence staining indicated that GLYAT was mainly expressed in the cytoplasm, particularly the mitochondria. Kaplan-Meier curves showed that the low protein expression of GLYAT was correlated with a poor prognosis in liver cancer and ccRCC patients. Moreover, GLYAT expression was associated with several clinical parameters in liver cancer. Cell experiments showed that the overexpression of GLYAT inhibited cell proliferation and migration abilities; however, interfering GLYAT protein expression rescued these abilities in GLYAT overexpression (GLYAT-OE) cells. In vivo assays confirmed the tumor-suppressor function of GLYAT in liver cancer. Moreover, our research showed that GLYAT downregulated Rho-associated coiled-coil-containing protein kinase 1 (ROCK1).Our study showed that GLYAT is lowly expressed in liver cancer and ccRCC, emphasizing its prognostic significance. It also showed that GLYAT inhibits the progression of liver cancer and ccRCC by downregulating ROCK1.2024 AME Publishing Company. All rights reserved.
基金：
This work was supported by the National Nature Science Foundation of China (No. 81972574), the Leading Talents of Tongren Hospital Fund (No. TRKYRC-lj202205), and the Medical-Engineering Combination Fund (No. 2023DHYGJC-ZDB01).
第一作者机构：[1]Hongqiao International Institute of Medicine, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
通讯作者：
推荐引用方式(GB/T 7714)：
Xia Yechen,Huang Wentao,Jin Guang-Zhi.GLYAT suppresses liver cancer and clear cell renal cell carcinoma progression by downregulating ROCK1 expression[J].Translational Cancer Research.2024,13(9):5097-5111.doi:10.21037/tcr-24-1412.
APA：
Xia Yechen,Huang Wentao&Jin Guang-Zhi.(2024).GLYAT suppresses liver cancer and clear cell renal cell carcinoma progression by downregulating ROCK1 expression.Translational Cancer Research,13,(9)
MLA：
Xia Yechen,et al."GLYAT suppresses liver cancer and clear cell renal cell carcinoma progression by downregulating ROCK1 expression".Translational Cancer Research 13..9(2024):5097-5111
